Real-World Outcomes in HER2-Positive NSCLC

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

In 2021, UnitedHealth Group received 42% of the $33 billion in additional Medicare Advantage payments from differential coding.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.